The source of MHC class I presented peptides and its implications

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F16%3AN0000032" target="_blank" >RIV/00209805:_____/16:N0000032 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.coi.2016.04.002" target="_blank" >http://dx.doi.org/10.1016/j.coi.2016.04.002</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.coi.2016.04.002" target="_blank" >10.1016/j.coi.2016.04.002</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The source of MHC class I presented peptides and its implications

Popis výsledku v původním jazyce

The source of peptides that enter the major histocompatibility class I (MHCI) pathway has been intensively debated over the last two decades. The initial assumption that peptides are derived from degradation of full length proteins was challenged by a model in which alternative translation products are a source of peptides. This model has been tested and supported by scientific data. We now need new hypotheses on the physiological implications of different sources of peptides for the MHCI pathway. The aim of this overview is to give an up-to-date account of the source of antigenic peptide material for the MHCI pathway and to incorporate the more recent observations of alternative mRNA translation products into existing models of the direct and cross-presentation pathways.

Název v anglickém jazyce

The source of MHC class I presented peptides and its implications

Popis výsledku anglicky

The source of peptides that enter the major histocompatibility class I (MHCI) pathway has been intensively debated over the last two decades. The initial assumption that peptides are derived from degradation of full length proteins was challenged by a model in which alternative translation products are a source of peptides. This model has been tested and supported by scientific data. We now need new hypotheses on the physiological implications of different sources of peptides for the MHCI pathway. The aim of this overview is to give an up-to-date account of the source of antigenic peptide material for the MHCI pathway and to incorporate the more recent observations of alternative mRNA translation products into existing models of the direct and cross-presentation pathways.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

<a href="/cs/project/LO1413" target="_blank" >LO1413: RECAMO2020</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Current Opinion in Immunology

ISSN

0952-7915

e-ISSN

—

Svazek periodika

40

Číslo periodika v rámci svazku

Jun 2016

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

6

Strana od-do

117-122

Kód UT WoS článku

000377836700017

EID výsledku v databázi Scopus

—